Phenytoin-induced cerebellar atrophy in an epileptic boy

Kumar, Nithin; Chakraborty, Ananya; Suresh, Swaroop Hassan; Basappaji, Sashidharan; Betdur, Anand L.

doi:10.4103/0253-7613.121388

Cited by 5 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Epilepsy, a prevalent neurological condition, aims to be effectively managed by treatment, with the primary objective being the control of seizures while minimizing adverse effects [4]. The potential for phenytoin intoxication is frequently attributed to its substantial pharmacokinetic variability and a low threshold for toxicity [5][6][7][8]. Intoxication typically presents with symptoms such as nausea and central nervous system dysfunction, marked by confusion, nystagmus, and ataxia.…”

Section: Introductionmentioning

confidence: 99%

Phenytoin-Induced Ataxia and Diplopia in a Patient with Recent Subarachnoid Hemorrhage: A Case Report

Karra,

Smaigdhini,

Sahithya

et al. 2024

JASR

View full text Add to dashboard Cite

This case report presents a 25-year-old male with a complex medical history, including a recent subarachnoid hemorrhage (SAH) and a prescription for phenytoin. The patient exhibited neurological symptoms, such as ataxia, blurring of vision, and diplopia, prompting an intricate diagnostic evaluation. The medical history encompassed a prior road traffic accident resulting in a jaw injury, adding to the complexity of potential aetiologies, including cerebellar dysfunction, sequelae from the accidents, medication-related side effects (particularly phenytoin), or infectious/inflammatory causes. Given the reported symptoms, there arose a suspicion of phenytoin-induced ataxia and diplopia, common neurological side effects associated with this anticonvulsant. These symptoms, suggestive of cerebellar dysfunction, required a comprehensive examination, including neurological assessments and imaging studies, to elucidate the precise etiology. This case underscores the importance of meticulous medication review, particularly for drugs like phenytoin, and emphasizes the necessity of a multidisciplinary approach involving neurologists to navigate the complexities associated with neurological manifestations in the context of SAH and medication use. The findings contribute to understanding potential complications arising from anticonvulsant therapy in SAH patients and highlight the need for tailored diagnostic and management strategies in such intricate clinical scenarios.

show abstract

Section: Introductionmentioning

confidence: 99%